Tag Archives: hospital

Changing cancer’s environment to halt its spread

The study team, led by Randolph Watnick, PhD, at Boston Children’s Hospital, Vivek Mittal, PhD, at Weill Cornell Medical College and Lars Akslen, MD, PhD, at the University of Bergen, released their findings in the May issue of the journal Cancer Discovery. The main cause of cancer mortality is not the primary tumor itself, but rather its spread — metastasis — to other locations in the body and subsequent organ failure. Previous studies by Watnick, a member of Boston Children’s Vascular Biology Program, and others have shown that tumors capable of metastasis release proteins that help prepare new homes in distant organs for their metastatic progeny. …

The DSM-5 is here: What the controversial new changes mean for mental health care

The most recent revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM) has arrived, and the latest changes have caused divisions among those in the psychiatric community.   Often touted as the psychiatrist’s “Bible,” the DSM is published by the American Psychiatric Association and establishes the almost universal standard by which doctors classify, diagnose and ultimately treat mental disorders – making it an essential part of the psychiatric profession.  The DSM is utilized not only by clinicians, but researchers and health insurance companies as well. Even government officials take interest in the DSM’s criteria in order to determine grant funding, insurance coverage and new health care policies. The latest version is the DSM’s fifth edition, and it is the manual’s first major revision in nearly 20 years since the publication of the DSM-IV in 1994.  The DSM-5’s release brings some radical new changes, which have been met with both praise and disgust from mental health professionals. Some of the most highly debated changes include the elimination of Asperger’s disorder and the addition of a few new controversial conditions such as cannabis withdrawal, gambling addiction and the highly contested disruptive mood dysregulation disorder (DMD). So what do these changes mean for those currently dealing with mental health disorders?  Read on to learn more about the DSM-5’s biggest changes and the possible impact they may have on mental health care. Combination of autism spectrum disorders into single category One of the most publicized changes in the DSM-5 involves grouping all of the subcategories of autism into a single category known as autism spectrum disorder (ASD).  This move effectively eliminates previously separate diagnoses of autism – including autistic disorder, Asperger’s disorder, childhood disintegrative disorder and pervasive development disorder “not otherwise specified” (PDD-NOS). This merging of categories creates a “sliding scale” for autism, meaning individuals will be diagnosed somewhere along the autism spectrum, given the personal severity of their symptoms. Many parents and health care providers have speculated that this transformation may end up excluding some of those already diagnosed with an autism disorder, like Asperger’s or PDD-NOS. “I think (exclusion from the spectrum) frankly yet to be determined, but if anything, the specificity is going to go up, meaning the false positives are going to be less likely,” Dr. Alexandar Kolevzon, associate professor of psychiatry and pediatrics at Mount Sinai Hospital in New York City, told FoxNews.com. “This universe of people with PDD-NOS – it’s possible that some of those patients may no longer meet those criteria.  Some of the debate revolves around Asperger’s, but it seems to me that most people diagnosed with Asperger’s will still be on the autism spectrum.” Over the past decade, the United States has seen a striking increase in the amount of autism diagnoses, with the Centers for Disease Control and Prevention estimating that one in 88 children suffers from an autism spectrum disorder.  According to Kolvezon, numerous epidemiological studies have found that the majority of children accounting for this incidence are those with PDD-NOS – a diagnosis given to those with communication issues and pattern behavior but who do not meet the full criteria for autism or another pervasive developmental disorder. Kolevzon said it’s possible that over-diagnosis of PDD-NOS has led to this increase in autism spectrum disorder cases. “What happens in the community is that the diagnosis of autism spectrum disorder virtually guarantees a whole host of therapies – such as speech therapy, occupational therapy, behavioral therapy, and potentially physical therapy,” Kolevzon said. “Theoretically, it’s possible that community providers and clinicians are incentivized to label kids with PDD-NOS, because it would make it more likely to receive appropriate services.” The autism spectrum disorder scale will further refine the way providers diagnose autism, Kolevzon said, by recognizing differences from person to person rather than trying to generalize them into one of four categories. The creation of disruptive mood dysregulation disorder Within the past decade, more and more children as young as 2 years old have been diagnosed with bipolar disorder, leading to the prescription of powerful antipsychotic medication that can be quite intense for children at such a young age. According to the Agency for Healthcare Research and Quality, hospital stays for childhood bipolar disorder have increased by 434 percent from 1997 to 2010.   The trend began in the mid-1990s, when doctors from Harvard University stated that bipolar disorder presented differently in children than that of adults. However, recent studies have found that many of these diagnoses were false, causing what many have described as the “false epidemic.” To combat this trend, the DSM-5 is eliminating the diagnosis of pediatric bipolar disorder and creating a brand new category called disruptive mood dysregulation disorder (DMDD), described as intense outbursts and irritability beyond normal temper tantrums in young children. While the move is meant to address an established problem, many are worried that the category will be applied too liberally. “My concern is this category will be applied to individuals where the reason for these blow ups is for something else.  You can see it in kids with anxiety disorders and ADHD….Even the head of the DSM committee asked, ‘Are we going to label kids with temper tantrums?’” Dr. Max Wiznitzer, a pediatric neurologist for UH Rainbow Babies & Children’s Hospital in Cleveland, Ohio, told FoxNews.com. “The thing is we have to make sure people are going to be rigorous in application and not just apply to any kid with temper tantrums or sleep deprivation.” ‘Dependence’ to ‘addiction,’ cannabis withdrawal and gambling disorders The DSM’s chapter on substance abuse has also undergone changes, now being called the Substance Use Disorders chapter.  The diagnostic criteria for these conditions have been expanded, but one of the biggest changes deals with the swapping of two seemingly similar words when describing these disorders: the term “dependence” is out and the term “addiction” is in. According to Dr. Yasmin Hurd, professor of psychiatry at Mount Sinai, the change is subtle but necessary. “It was quite confusing, especially with the term dependence,” Hurd told FoxNews.com.  “It had association with severe psychological dependencies, generating a lot of confusion.  Now the DSM-5 just talks about addiction, in context, being about the compulsive nature of the disorder.” For example, patients being prescribed pain medication may wind up hooked on the drug, but they are still taking the medication under the guidance of a physician.  They aren’t necessarily seeking out the medication by themselves, but if they are taken off the drug they may still have psychological withdrawal. In this case, they aren’t dependent on the drug, but they are addicted - according to the new guidelines. In addition to the word swap, new controversial categories of gambling disorders and cannabis withdrawal have been created in the DSM-5 – decisions based on multiple human and animal studies. “Experts in the field know that people who have severe cannabis use – they’ll go through cannabis withdrawal,” Hurd said. “There is a misnomer in our society that people can’t get addicted to marijuana.  That’s not true.  There are more people that meet the criteria for abuse of cannabis than any other illicit drug.” Similar to the changes made to the autism spectrum disorders, substance use disorders will also be categorized more on a sliding scale, depending on the severity of each patient’s symptoms. “You’re going to have many people with alcohol and cannabis addiction who have mild addiction, but very few heroin addicts are going to be mild,” Hurd said. Other major changes Along with the more controversial changes, the DSM-5 is also refining the criteria for post-traumatic stress disorders (PTSD), including a subtype for PTSD in preschool children.  The diagnosis for attention deficit hyperactivity disorder is also getting a revision, with the elimination of a previously required symptom and the changing of the required age of onset from age 7 to age 12. Obsessive compulsive disorder (OCD), once categorized under anxiety disorders, is now getting its own category of Obsessive-compulsive and related disorders.  Along with OCD, this category includes Body Dysmorphic Disorder (BDD), Trichotillomania (TTM, or hair pulling) and a brand new disorder called Hoarding Disorder. The DSM-5 incorporates many more changes that have psychiatrists locked in heated debate, but Wiznitzer noted that these tensions will always exist as long as doctors continue to learn more about the human brain. “Homosexuality used to be in the DSM as a psychiatric disorder; that was two versions ago,” Wiznitzer said. “Autism wasn’t even in the first two versions of the DSM, it was childhood schizophrenia.  Then we changed the criteria over time.  Basically anytime you change something, it’s always met with resistance.” Click for more information on the DSM-5.source : http://www.foxnews.com/health/2013/05/21/dsm-5-is-here-what-controversial-new-changes-mean-for-mental-health-care/

Commonly used catheters double risk of blood clots in ICU and cancer patients

But compared to other central venous catheters (CVCs), these commonly-used catheters (known as PICCs) more than double the risk of dangerous blood clots — especially among patients who are critically ill or who have cancer, according to a new University of Michigan Health System study published in The Lancet. …

Not my kid: Most parents unaware teen is using study drugs

Many parents are not aware that their teenage children abuse “study drugs,” a new poll suggests. In the poll, just 1 percent of parents said their teenage children had taken drugs such as Adderall or Ritalin without a prescription. That is much lower than the percentage of teens that surveys suggest are using the drugs. For example, a 2012 study of high schoolers found that about 10 percent of sophomores and 12 percent of seniors said they had used the drugs without a prescription. The new finding highlights the growing issue of stimulant drug abuse, or when teens take stimulant medication (or “study drugs”) to help them study for a test or stay awake to do homework. Such medications are prescribed for attention deficit hyperactivity disorder (ADHD). Teens without the condition may fake symptoms in order to get a prescription, or obtain the drugs from friends. The new findings, from the C.S. Mott Children's Hospital National Poll on Children's Health, examined parents' awareness of the issue, surveying parents of U.S. children ages 13 to 17. About 11 percent of parents said their teens had been prescribed stimulant medication for ADHD. Among parents of children who were not prescribed ADHD medications, 1 percent said their teens had used these drugs for study purposes. About 4 percent said they didn't know if their teen had abused these drugs, and 95 percent said their teens had never abused the drugs. This disconnect between teen drug abuse and parents' awareness of drug abuse may be in part due to the fact that study drugs have more subtle effects than drugs such as heroin and cocaine, allowing teens to more easily hide their drug use, the researchers said. About half of parents polled said they were very concerned about teens in their communities abusing study drugs. And more than three-quarters supported school policies aimed at stopping this type of drug abuse, such as rules that would require children with prescription ADHD medications to keep the pills in a secure place like the school nurse's office. The findings “underscore the need for greater communication among public health officials, schools, parents, and teens regarding this issue,” the researchers said. Follow Rachael Rettner @RachaelRettner. Follow MyHealthNewsDaily @MyHealth_MHND, Facebook & Google+. Originally published on LiveScience.Copyright 2013 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.source : http://www.foxnews.com/health/2013/05/20/not-my-kid-most-parents-unaware-teen-is-using-study-drugs/

Brain makes call on which ear is used for cell phone

The study — to appear online in JAMA Otolaryngology-Head & Neck Surgery — shows a strong correlation between brain dominance and the ear used to listen to a cell phone. More than 70% of participants held their cell phone up to the ear on the same side as their dominant hand, the study finds. Left-brain dominant people — who account for about 95% of the population and have their speech and language center located on the left side of the brain — are more likely to use their right hand for writing and other everyday tasks. Likewise, the Henry Ford study reveals most left-brain dominant people also use the phone in their right ear, despite there being no perceived difference in their hearing in the left or right ear…

The golden rules of sun protection

Unless you've been living under a rock, you know to apply sunscreen. There's a lifesaving reason to: About 3.5 million cases of skin cancer will be diagnosed this year. “The incidence of skin cancer, including melanoma—the deadliest kind—is going up, and wearing sunscreen is one of the best ways to prevent it,” said Dr. Ronald Moy, a dermatologist and spokesperson for the Skin Cancer Foundation. Stick with these smart tips—and check out our product picks—to make sure you're as protected as you can possibly be. Select a sunscreen you love Finding your sunscreen soul mate is the key motivating factor for using it regularly, experts agree. “If you think your sunscreen is pasty, thick or smelly, you have the wrong kind,” said Dr. Jeffrey Dover, clinical associate professor of dermatology at Yale University. “It may make you less likely to put it on, or to reapply when you do.” Happily, there are plenty of lightweight, sheer formulas, like Vichy Capital Soleil Foaming lotion SPF 50 ($29; vichyusa.com) and La Roche-Posay Anthelios 60 Ultra Light sunscreen fluid for face SPF 60 with Cell-Ox Shield XL ($30; laroche-posay.us). Health.com: Which Sunscreen Is Best For You? Remember, SPF 30 is the new 15 As a general rule, SPF 15 blocks 93 percent of UVB rays, SPF 30 blocks 97 percent and SPF 50 blocks 98 percent. Doctors now typically recommend at least SPF 30—at least being the key words. If you have a family history of skin cancer or are vacationing in a tropical spot (where the sun is especially intense), go for 50 or even 70. Just keep in mind: No sunscreen provides 100 percent protection. So to be as safe as possible, you still need to reapply every two hours and after a swim, even if you used the water-resistant kind, said Dr. Joshua Zeichner, director of cosmetic and clinical research in dermatology at Mount Sinai Hospital in New York City. Try Neutrogena Beach Defense sunscreen spray broad-spectrum SPF 30 ($11; at mass retailers). FYI, sunscreen becomes less effective about three years after you open the container. Check labels for the term broad-spectrum It means the sunscreen provides protection against both UVA (wrinkle- and cancer-causing) and UVB (burning) rays. Problem is, that labeling rule only went into effect in December and stores still sell inventory made prior to it, noted Dr. Steven Wang, director of dermatologic surgery and dermatology at Memorial Sloan-Kettering Cancer Center in Basking Ridge, N.J.  So if you're shopping and there's no broad-spectrum mention, check the ingredients for zinc or avobenzone, the only two that provide top-notch UVA coverage, he says. Coola Mineral Sport broad-spectrum SPF 35 Citrus Mimosa ($36; coolasuncare.com) contains zinc, and L'Oréal Paris Sublime Sun Liquid Silk Sunshield for face broad-spectrum SPF 30 ($10; at mass retailers) has avobenzone. Health.com: 7 Ways You're Aging Your Skin Layer it on Think you apply enough

New cancer tools allow patients to reconsider chemo

After decades of using one-size-fits-all therapies to combat cancer, doctors are using new tools to help decide when their patients can skip chemotherapy or other harsh treatments. An approach to oncology that has been in place for decades is beginning to yield to an arsenal of long-term clinical studies, genetic tests and novel drugs that target cancer cells and their infrastructure. “What is happening is a combination of new technology and more-targeted cancer drugs,” said Dr Sandra Swain, medical director of the Cancer Institute at Washington Hospital Center and president of the American Society of Clinical Oncology (ASCO). “We've tried the approach of big, nonspecific treatments ... We have found that throwing chemo at patients has not (necessarily) cured them.” Traditional chemotherapy drugs work by interfering with the entire body's system of cell replication, causing harsh side effects like fatigue and hair loss. Since the completion of the human genome project in 2003, scientists have made progress in unlocking the genetic basis of a range of diseases, including cancer. That has paved the way for genetic testing as well as drugs that block specific pathways that cancer cells use to grow and reproduce. Such targeted cancer drugs, which sometimes preclude the need for chemotherapy, are being sold by companies ranging from Pfizer Inc, the world's largest drugmaker, to Ariad Pharmaceuticals Inc, which early this year launched its first drug, to treat leukemia. At the same time, large-scale studies that look at whether some types of patients are better off with less treatment are giving doctors more confidence to hold off on using traditional cancer drugs. Laurie Levin, now 64, was successfully treated in her 20s for non-Hodgkin's lymphoma, but faced a dilemma after being diagnosed with breast cancer in 2005 since the earlier radiation and chemotherapy had already raised her risk of developing heart problems or leukemia. A $4,000 genetic test showed that her breast cancer was unlikely to return, providing the confidence to undergo a lumpectomy and avoid chemotherapy. “It was like someone handed me my life back when I got those results,” she said. Use of the Oncotype DX test, which analyzes genes involved in tumor recurrence, has cut the use of chemotherapy in U.S. breast cancer patients by 20 percent over the past eight years, according to its maker, Genomic Health Inc. The company recently launched a similar test designed to measure whether men with prostate cancer need to undergo surgery or radiation. Tests and studies can clarify treatment, but costs remain on the upswing because the newest drugs are very expensive, with monthly price tags often in the thousands of dollars. By 2016 annual global sales of cancer drugs will nearly triple, to $88 billion from a decade earlier, according to IMS Health. 'RIGHT-SIZING TREATMENT' The “less is more” approach to cancer will be one highlight of ASCO's annual meeting in Chicago that begins at the end of this month. On Wednesday, ASCO released thousands of abstracts on new clinical trials of cancer treatments. One large, long-term study found that most men diagnosed with early-stage seminoma, a common type of testicular cancer, did fine with no treatment following surgery to remove the tumors. Cure rates for the disease have always been quite high. Several European countries, including Denmark where the study was conducted, monitor seminoma patients for any relapse before further treatment. In the United States, about half of early-stage patients are still given radiation or chemotherapy, according to ASCO. “Opting for surveillance spares patients, most of whom are young men, from the harmful side effects of chemotherapy and radiation without diminishing their chances for a long and healthy life,” said ASCO's incoming president, Dr Clifford Hudis, in a statement. Physicians say it is difficult to quantify in statistics, but there is growing recognition that less is more in terms of potentially toxic cancer treatments. The approach is especially important for young patients who will have many years ahead of them after beating an initial bout of cancer. “We are right-sizing treatment,” said Dr. James Mohler, chair of the department of urology at Roswell Park Cancer Institute in Buffalo, New York. He pointed to recent national guidelines calling for “active surveillance” of older men diagnosed with slower-growing prostate cancer. A study presented earlier this year at an ASCO meeting in Florida found similar survival rates for men with high-risk prostate cancer who received radiation and either 18 or 36 months of hormone therapy. The findings suggest the therapy, which causes significant side effects, could be given for less than the current standard of 24 to 36 months. Another recent study out of the Duke Cancer Institute in Durham, North Carolina, found that survival odds for women with early-stage breast cancer who underwent breast-preserving surgery such as lumpectomy were as good as, or even better than, the odds for women who had mastectomies. “We are going to see reevaluations of very successful therapies to determine whether or not we can achieve the same results using less treatment,” said Dr Armand Keating, director of the hematology division at the University of Toronto and president of the American Society of Hematology. The first-ever study showing that a type of leukemia could be cured without using chemotherapy was released in December. The Italian-German study found that a combination of a derivative of vitamin A, known as ATRA, and arsenic trioxide, a newer drug, worked as well as ATRA and chemotherapy in patients newly diagnosed with acute promyelocytic leukemia (APL). “APL used to be one of the most dreaded strains of cancer, but with ATRA and chemo the results are very gratifying,” Keating said. “Now we have two agents that are not chemo agents ... That to me is a milestone. I can't see any reason why this wouldn't become the standard of care.” A recent trial conducted in France found that omitting standard chemotherapy, which has been linked to heart damage, from the initial treatment of a type of childhood leukemia did not reduce survival outcomes. “The nice thing is you have omitted a potentially toxic agent that contributes to morbidity and maybe mortality down the road,” Keating said. The priciest therapies are designed to take advantage of genetic mutations associated with cancer cells, some of them found only in a small percentage of patients. A new drug for melanoma, BRAF inhibitor Zelboraf from Roche Holding AG, is designed to work by targeting a specific genetic mutation found in about half of all melanomas. Patients are first tested to see if they have it. Pfizer's lung-cancer drug Xalkori, which targets a mutation in the ALK gene, works in about 4 percent of lung cancer patients. It also has been effective as a treatment for a rare but aggressive type of childhood lymphoma. “We've been really trying for years to be more precise about who needs treatment ... Now we are more able to achieve it,” said Swain.source : http://www.foxnews.com/health/2013/05/16/new-cancer-tools-allow-patients-to-reconsider-chemo/

Hysterectomy not tied to heart risk factors, study shows

Despite evidence suggesting that women whose uterus has been removed may be more likely to experience heart troubles, a new study finds that the usual signs of heart disease risk are not more severe in middle-aged women after hysterectomy. After following more than 3,000 women for about 11 years, researchers found that heart risk factors like cholesterol, markers of inflammation and blood pressure were not significantly worse in women in the years following an elective hysterectomy, compared to women who did not have the procedure. “I think it's encouraging to women and clinicians that this is not something they have to worry about if they're considering hysterectomy (in) midlife,” said Karen Matthews, the study's lead author from the University of Pittsburgh. Hysterectomy, the surgical removal of the uterus, is the second most common surgery among U.S. women, after cesarean-section deliveries. Often the procedure is used to remove or prevent cancer, especially among younger women. But many women may elect to have the surgery for other reasons, including to treat painful benign growths in the uterine wall known as fibroids or to staunch heavy bleeding. Hysterectomies can involve removal of the uterus only, or the ovaries as well. Ovary removal in particular has been linked to increased cardiovascular risk because it takes away the main source of estrogen in a woman's body and plunges her abruptly into menopause. Even the gradual decline of estrogen following natural menopause has been linked to women's increased heart risks, so researchers have investigated whether hysterectomy raises those risks. But studies of the connection have produced mixed results. For the new study, Matthews and her colleagues used data from the Study of Women's Health Across the Nation, which followed a large, multiethnic group for more than a decade to understand the experience of American women during and after menopause. The 1,952 women included in the study were between 42 and 52 years old and not yet in menopause when tracking began. They were followed from 1996 through 2008, receiving annual checkups that recorded information about their health, surgeries and whether or not they had started menopause. Specifically, the researchers looked at physical measurements that are markers for heart and cardiovascular disease. They included various components of cholesterol, blood pressure, blood clotting factors and molecules that are signals of inflammation. Overall, the researchers report in the Journal of the American College of Cardiology that none of those measurements in the 183 women who chose to have their uterus removed - with or without their ovaries - were significantly worse, compared to the 1,769 women who went through menopause naturally. Matthews said their findings apply to women who are finished having children, in their forties and are considering a hysterectomy to help with excessive bleeding or other factors that cause a quality of life problem. She said they couldn't make a conclusion for women who need to have their uterus and ovaries removed because of cancer. “Our study really couldn't examine that question because we had too few women who had gynecological cancers, and the equation changes when you have gynecological cancer,” said Matthews. But Dr. JoAnn Manson, who has researched women's health after hysterectomy but was not involved in the new study, suggested the results don't mean that women who have hysterectomies are in the clear, because past studies only saw a difference in heart risks after 10 to 15 years. Manson, who is chief of preventive medicine at Brigham and Women's Hospital in Boston, told Reuters Health that the abrupt transition to menopause after a hysterectomy may only reverberate years later because “atherosclerosis takes a while to develop… That seems to take up to 10 and 15 years for clear differences to emerge.” For that reason, “This isn't totally surprising that there wasn't a difference in risk factors during the follow up period,” Manson said. Matthews said that's one potential explanation for why their results differ from previous studies, but she said there could be other reasons, including that modern women are somehow different from women included in past research. “It may be that it's emerging much later, but I would be surprised,” Matthews said.source : http://www.foxnews.com/health/2013/05/15/hysterectomy-not-tied-to-heart-risk-factors-study-shows/

Fish oil doesn’t seem to help age-related macular degeneration

Another key finding of the Age-Related Eye Disease Study 2, or AREDS 2, is that lutein and zeaxanthin may be safer than beta-carotene in reducing risk of disease progression. "If you look at all the analysis performed in the AREDS 2 study, it looks like lutein taken with zeaxanthin is at least as effective and may be better than beta-carotene," Brown said. "If you also consider that beta-carotene was associated with increased lung cancer rates in all former smokers, I no longer recommend any formulations containing beta-carotene." Researchers saw a modest decrease in the development of age-related macular degeneration (AMD) among those who took high amounts of zinc, but that result was not statistically significant. …

Small amounts of formula may promote breastfeeding in some babies

Feeding newborn babies small amounts of carefully regulated formula before a mother’s milk comes in does not disrupt the child’s ability to breastfeed – and may ultimately improve breastfeeding success in the future, the New York Times reported. In a new study published in the journal Pediatrics, researchers examined 38 newborns who had lost 5 percent or more of their body weight in the first few days after birth.  Each infant was randomly assigned to either breastfeed alone or breastfeed along with a formula supplement – administered through a syringe to avoid so-called “nipple confusion” between the mother’s nipple and the bottle’s nipple. This concept is up for debate among mothers and pediatricians.  The supplement was given after a feeding, to boost the child’s hunger for the next breastfeeding. After the first week of observation, all of the babies were still breastfeeding, but nine of the 19 infants who began exclusively with breastfeeding were now using formula.  After three months, 79 percent of the babies who had been given an early formula supplement were breastfeeding exclusively, compared to 42 percent of those who had begun with just breastfeeding. Many mothers and doctors encourage women to exclusively breastfeed their children, but this new study suggests small amounts of formula may help struggling newborns get the nutrition they need in the early stages of life. “Most babies don’t need formula,” said the lead author, Dr. Valerie J. Flaherman, a pediatrician at the University of California, San Francisco, Benioff Children’s Hospital. “But some kids are at risk for weight loss, and this could be an option.” Click for more from the New York Times.source : http://www.foxnews.com/health/2013/05/13/small-amounts-formula-may-promote-breastfeeding-in-some-babies/